Abstract: Stress-induced premature cellular senescence is a significant factor in the onset of age-dependent disease in the cardiovascular system. Plasminogen activator inhibitor-1 (PAI-1), a major TGF-β1/p53 target gene and negative regulator of the plasmin-based pericellular proteolytic cascade, is elevated in arterial plaques, vessel fibrosis, arteriosclerosis, and thrombosis, correlating with increased tissue TGF-β1 levels. Additionally, PAI-1 is necessary and sufficient for the induction of p53-dependent replicative senescence. The mechanism of PAI-1 transcription in senescent cells appears to be dependent on caveolin-1 signaling. Src kinases are upstream effectors of both FAK and caveolin-1 activation as FAK Y577,Y861 and caveolin-1 Y14 phosphorylation are not detected in TGF-β1-stimulated src family kinase (pp60 c-src , Yes, Fyn) triple-deficient (SYF −/−/− ) cells. However, restoration of pp60 c-src expression in SYF-null cells rescued both caveolin-1 Y14 phosphorylation and PAI-1 induction in response to TGF-β1. Furthermore, TGF-β1-initiated Src phosphorylation of caveolin-1 Y14 is critical in Rho-ROCK-mediated suppression of the SMAD phosphatase PPM1A maintaining and, accordingly, SMAD2/3-dependent transcription of the PAI-1 gene. Importantly, TGF-β1 failed to induce PAI-1 expression in caveolin-1-null cells, correlating with reductions in both Rho-GTP loading and SMAD2/3 phosphorylation. These findings implicate caveolin-1 in expression controls on specific TGF-β1/p53 responsive growth arrest genes. Indeed, up-regulation of caveolin-1 appears to stall cells in G 0 /G 1 via activation of the p53/p21 cell cycle arrest pathway and restoration of caveolin-1 in caveolin-1-deficient cells rescues TGF-β1 inducibility of the PAI-1 gene. Although the mechanism is unclear, caveolin-1 inhibits p53/MDM2 complex formation resulting in p53 stabilization, induction of p53-target cell cycle arrest genes (including PAI-1), and entrance into premature senescence while stimulating the ATM→p53→p21 pathway. Identification of molecular events underlying senescence-associated PAI-1 expression in response to TGF-β1/src kinase/p53 signaling may provide novel targets for the therapy of cardiovascular disease.
Introduction: Vascular smooth muscle cell (VSMC) Senescence and Vascular Disease
Tissue-resident cells acquire the morphologic and biochemical hallmarks of a senescent phenotype during development of several age-related disorders including atherosclerosis, idiopathic lung fibrosis, chronic obstructive pulmonary disease, osteoarthritis, Alzheimer's and Parkinson's disease, cancer, and renal fibrosis [1] [2] [3] [4] . In the cardiovascular system, stress-induced premature cellular senescence is a major contributor to the onset of age-dependent pathologies and compromised vessel function [4, 5] . Vascular disease remains the predominant cause of mortality worldwide, particularly in western industrialized countries where chronological age is the most significant risk determinant [6] . Estimates suggest that more than one-third of the population 40 to 60 years old and 83% of those over 85 have some form of cardiovascular disease [4] . Plaque-associated VSMCs exhibit other molecular traits characteristic of the senescent state including induction of the cell cycle inhibitors p16 and p21, reduced E2F transcriptional activation of proliferation-promoting genes due to retinoblastoma (Rb) protein hypophosphorylation and up-regulation of p53 [14] [15] [16] 22] . There is some controversy as to the actual role of p53 in age-related disorders [13] ; however, p53 is a critical factor in vessel pathophysiology and down-modulates cellular levels of the telomere protective repeat-binding protein 2 (TRF2), likely via a p53-dependent ubiquitin ligase [23] . Plaque VSMCs have shortened telomeres and decreased TRF2 levels. Overexpression of a functional TRF2 construct results in a senescence bypass, reduces DNA damage, accelerates repair, and attenuates the extent of vascular disease compared to a loss-of-function TRF2 mutant which exacerbates atherosclerosis and necrotic core formation [23] . p53 activation also sensitizes VSMCs to Fas-mediated apoptosis by increasing cell surface Fas levels. This has significant consequences; unlike viable VSMCs which promote plaque stability via maintenance of collagen expression, a major determinant of the fibrous cap tensile strength perhaps in response to elevations in vessel TGF-β levels, apoptotic VSMCs contribute to plaque vulnerability while simultaneously functioning as nucleating structures for vascular calcification [14] . Indeed, senescent VSMCs overexpress osteoblastic genes (e.g., alkaline phosphatase, RUNX-2, type I collagen, BMP-2) suggesting that acquisition of a pro-calcificatory phenotype is one aspect of a cell type-exclusive senescence program in the vascular system [24, 25] .
Caveolin-1 and the Senescent Phenotype: Involvement of p53
Up-regulation of caveolin-1 is evident in senescent cells and linked to several age-related diseases [18, 26] . Overexpression approaches implicate caveolin-1 in the development of premature senescence in primary fibroblasts [27] , the acquisition of senescence-associated morphologic restructuring [28] , and the stalling of cells in G 0 /G 1 by activation of the p53/p21 cell cycle arrest pathway [29] . The precise mechanism(s) underlying caveolin-1-associated p53 mobilization and involvement in cellular senescence may vary as a function of cell type and the nature of the arrest state, oxidative stress promotes interactions between caveolin-1 and the dual-site E3 ubiquitin ligase mouse double minute 2 homolog (MDM2); however, a major negative regulator of p53 transcriptional activity and stability [30] . The MDM2 caveolin-1 binding domain overlaps with the p53 binding motif of MDM2, suggesting that caveolin-1 may inhibit p53/MDM2 complex formation resulting in p53 stabilization, upregulation of p53-target growth arrest genes (e.g., p21, plasminogen activator inhibitor-1), and entrance into premature senescence [26, 31, 32] . Introduction of a peptide corresponding to the MDM2 binding region of caveolin-1 has a comparable effect while oxidative stress-induced activation of the p53/p21pathway and senescence induction are mitigated in caveolin-1-null mouse embryonic fibroblasts [32] . Enhanced interaction between caveolin-1 and MDM2 is also evident in diabetic fibroblasts which have a significantly decreased antioxidant capacity and exhibit both a heightened level of oxidative stress and a senescence-like phenotype [33] . Caveolin-1 knockdown attenuates diabetes-associated premature senescence and p53/MDM2 complex formation. However, ATM is also a critical regulator of stress-induced p53 and the p53 signaling pathway [2] . Caveolin-1 activates ATM likely by sequestering PP2A, which negatively regulates ATM autophosphorylation, into caveolar structures thereby stimulating engagement of the ATM→p53→p21 pathway [26] . These data indicate that, under conditions of oxidative stress-induced senescence, caveolin-1 down-regulates p53/MDM2 binding while promoting ATM function collectively activating p53/p21 signaling and subsequent growth arrest. Although specific clinical-grade drugs are not yet available, senolytic targeting of the p53/p21 network, perhaps via inhibition of p53/FOXO4 interactions or knockdown of the p53 responsive p21 gene [34] , may have potential clinical utility in the context of caveolin-1-induced vascular cell senescence and vessel pathology. The therapeutic implications of such approaches may also be relevant to p53-associated mechanisms of vascular disease other than those initiated as a consequence of caveolin-1 deregulation. Indeed, expression of the actin-binding smooth muscle protein SM22α in VSMCs is increased upon chronic Angiotensin II treatment [35] . SM22α overexpression induces VSMC senescence, a response that is p53 dependent. Elevated levels of SM22α inhibit p53 ubiquitination and degradation by attenuating PI3K/Akt-mediated phosphorylation and activation of MDM2 decreasing interactions between MDM2 and p53 resulting in p53 stabilization [35] .
Caveolin-1 Signaling Is Required for Expression of the Senescence-Inducing p53-Target PAI-1 Gene in VSMCs
Plasminogen activator inhibitor type-1 (PAI-1, SERPINE1) is a major promoter of vascular-related pathologies, including arterial thrombosis and perivascular fibrosis [36, 37] as well as a biomarker and prognostic indicator of TGF-β1-stimulated neointima formation and disease progression [21, 36, [38] [39] [40] . In some cell types, including VSMCs, TGF-β1 functions as a senescence driver. Recent findings suggest that TGF-β1 induces VSMC senescence through reactive oxygen species-stimulated activation of the NF-κB signaling pathway and expression of SASP factors, including PAI-1 [41, 42] . Transgenic mice that overexpress PAI-1 develop age-dependent atherosclerosis while PAI-1-deficient animals are protected from experimentally induced vascular disease [37] . Importantly, PAI-1 is not merely a biomarker of the senescent phenotype but is necessary and sufficient for the induction of replicative senescence downstream of p53 [43] and is a key inducer of the senescence program [44] . Indeed, PAI-1 is consistently among the highest up-regulated genes in all models of induced senescence, confirming its causative involvement in age-related disease [45, 46] . Consistent with this implication, a loss of function frameshift mutation in the PAI-1 gene in an Old Order Amish community is associated with telomere length, lower incidence of diabetes, and longer life span [47] . Moreover, exogenously delivered PAI-1 alone stimulates TGF-β1 synthesis, suggesting the existence of a PAI-1/TGF-β1-positive feed-forward mechanism [48] . This provides for a model whereby elevated tissue levels of TGF-β1 during the emergence of the senescent phenotype stimulate expression of PAI-1 that, in turn, reinforces continued TGF-β1 synthesis promoting the maintenance, and perhaps expansion, of the senescent VSMC population. Targeted down-modulation of PAI-1 expression or function may be one approach to inhibit the onset and progression of vascular fibrosis.
The mechanism of PAI-1 transcriptional activation in cellular senescence [49, 50] is less clear but appears to be dependent on caveolin-1 signaling [51] , as seen in Figure 2 . Cooperation between non-SMAD (i.e., pp60 c-src -EGFR-ERK1/2) pathways and SMAD signaling is necessary for maximal TGF-β1-stimulated PAI-1 transcription [52] [53] [54] [55] . TGF-β1-induced Rho-ROCK activation, for example, affects the duration, but not the initiation, of SMAD2/3 phosphorylation; however, the underlying molecular basis and impact on TGF-β1 target gene expression is unknown [51] . Furthermore, TGF-β1-mediated Rho-activation is repressed in caveolin-1-null cells, perhaps due to deficient caveolin-1/caveolae-dependent TGF-β1 receptor interactions and internalization [56] . However, Caveolin-1 appears necessary for TGF-β1-mediated fibronectin expression in mesangial cells, suggesting that caveolin-1 regulation of TGF-β1 signaling may be context-dependent as well as cell type-specific. This possibility is supported by an analysis of conflicting findings. In some cells, caveolin-1 appears to attenuate TGF-β signaling through interaction with the TGF-β type I receptor inhibiting SMAD2/3 phosphorylation, down-regulation of TGF-β type II receptor expression, increased receptor internalization as well as degradation and interference with latent TGF-β activation [57] . In mouse embryonic fibroblasts, caveolin deficiency results in acquisition of a senescent-like phenotype through the p53-p21 pathway [58] ; however, in primary fibroblasts, overexpression of caveolin-1 induces the p53-p21 growth arrest program [27] [28] [29] . TGF-β1 activates p53 and both caveolin-1 and p53 are required for expression of the profibrotic p53 target PAI-1 gene and VSMC senescence [51, 59] ; accordingly, there are considerable cell type-dependent controls on the specific involvement of caveolin-1 in growth regulation, entry into a senescent state, and transcription of cell cycle arrest genes.
1 Figure 2 . A model illustrating the maintenance of induced SMAD3 phosphorylation and PAI-1 transcription in response to TGF-β1 via Src/p53/FAK/Caveolin-1 signaling. Binding of TGF-β1 to the TGF-β receptor (TGF-βR) stimulates the generation of reactive oxygen species (ROS) and activates Src kinases. Src phosphorylates caveolin-1 at Y14 and transactivates the EGFR at the Src target Y845 residue, leading to mobilization of the MEK-ERK and p38 (not shown) pathways. TGF-β1-initiated Src kinase phosphorylation of caveolin-1 Y14 also stimulates FAK activation, Rho-GTP loading, and Rho-ROCK activation at sites of integrin/matrix engagement. pCaveolin-1 Y14 -Rho-ROCK signaling inhibits PTEN-PPM1A interactions, resulting in a reduction of the SMAD phosphatase PPM1A, maintaining pSMAD2/3 levels required for PAI-1 induction and persistent expression in response to TGF-β1. ROS-mediated ATM activation stimulates p53 phosphorylation and recruitment of p-p53 to the promoter region of genes with p53 binding motifs [31, 51, 53, 59] . The PE2 region E box in the PAI-1 promoter is a docking site for the helix-loop-helix transcription-leucine zipper factors USF1/2 which are activated by MAP kinases as well as other TGF-β1-induced kinases. Members of the USF family reorient the DNA minor grove, promoting interactions between SMAD2/3 tethered to the PE2 region SMAD-binding elements (SBEs) with tetramerized p53, bound to its downstream half-site motifs [51, 59] . Occupancy of the immediate 5" upstream SMAD-binding elements (SBEs) with SMAD2/3/4 and co-localization with p53, USF2, and the histone acetyltransferases CBP/p300 facilitates the formation of a multi-component transcriptional complex required for TGF-β1-induced PAI-1 expression.
Mechanisms of Caveolin-1 Signaling
Caveolin-1 scaffolds spatially position and functionally regulate an increasing repertoire of effector molecules [60, 61] ; however, the available data differ regarding mechanism and imply that the specific role of caveolin-1 in signaling may be cell lineage-dependent. SMAD2/3 phosphorylation and PAI-1 induction in response to TGF-β1 is suppressed by genetic deficiency of caveolin-1 [51, 62] , likely a result of elevated expression of the transcriptional co-repressor SnoN [62] , implicating caveolin-1 as an activator of the Rho-ROCK-SMAD2/3 pathway [51] . Significantly reduced SMAD3 phosphorylation and increased expression of the SMAD phosphatase PPM1A expression in triple-deficient (pp60 c-src , Yes, Fyn) src kinase (SYF −/−/− ) cells correlates with reduced PAI-1 levels [51] . Src kinase-mediated FAK Y577 and Y861 phosphorylation is stimulated by TGF-β1; although FAK Y397 autophosphorylation is src-independent, FAK is both involved in and required for caveolin-1 Y14 phosphorylation, pSMAD3 activation, and PAI-1 expression [51] . Genetic reprogramming in response to TGF-β1utilizes SMAD (canonical) as well as non-SMAD (non-canonical) pathways [19, 53, [63] [64] [65] ; although the role of SMADs as transcriptional effectors of TGF-β1signaling is well established, how non-SMAD elements (e.g., Rho-ROCK, src kinases, FAK, caveolin-1) integrate into the more traditional canonical SMAD pathways is likely cell type-and target gene-dependent. Src kinases are critical upstream regulators of FAK and caveolin-1 activation as FAK Y577 and FAK Y861 and caveolin-1 Y14 phosphorylation are undetectable in TGF-β1 stimulated SYF −/−/− mouse embryo fibroblasts. However, pp60 c-src restoration in the SYF-deficient genetic background rescues both TGF-β1-induced caveolin-1 Y14 phosphorylation and PAI-1 expression [51] . Although the PAI-1 gene is unresponsive to TGF-β1 stimulation in caveolin-1-null fibroblasts, re-expression of a caveolin-1 construct in caveolin-1 -/-cells rescues PAI-1 inducibility. The mechanism of gene regulation downstream of caveolin-1 is unclear; however, TGF-β1 promotes interaction between RhoA and caveolin-1 leading to RhoA activation. Such synergy is attenuated in caveolin-1-deficient fibroblasts [51, 57] . Moreover, TGF-β1-dependent PAI-1 expression in hepatic epithelial cells similarly requires cooperation between caveolin-1 and SMAD2/3 [62] . Finally, TGF-β1-initiated mobilization of the src-FAK-caveolin-1-SMAD3 pathway and target gene transcription requires generation of reactive oxygen species (ROS) linking modulation of the cellular redox state to gene reprogramming [51] , similar to events underlying development of the senescent VSMC phenotype [41, 42] .
Controversies and Conclusions
Spatiotemporal signal switching, e.g., [66] involving the redirection, duration, and compartmentalization of caveolin-1 participation in EGFR versus RhoA activation and EGFR, src kinase p53 mobilization, likely dictates the specific caveolin-1 contribution to the senescent versus proliferative phenotypes. Outcome confounders include the cell type, whether normal or transformed, degree of "plasticity", the networks engaged, and the level of caveolin-1 expressed e.g., [67] . Indeed, caveolin-1 deficiency can also induce cellular senescence by initiating mitochondrial dysfunction, impairing mitochondrial respiration and inactivating SIRT1 [68] . This pathway, like the p53-dependent transcriptional response [43] , also involves activation of the p53→p21 growth arrest program [58] .
The caveolin-1/src kinase/EGFR triad involves interaction of the EGFR with caveolin-1 and phosphorylation of caveolin-1 Y14 by src [68] [69] [70] and can both positively and negatively regulate EGFR activation e.g., [51, 70] . The mechanisms underlying these divergent findings are unclear but likely are a result of the differences in cell type and the pathways impacted. However, Caveolin-1 is a transcriptional target of hypoxia-inducible factors 1 and 2, resulting in increased EGFR dimerization within caveolae and ligand-independent receptor activation stimulating cell proliferation and migration [71] . EGF signaling to RhoA also requires src kinases, is galectin 3-/p-caveolin-1 Y14 -dependent, and leads to increased cell migration [72] . This pathway induces actin reorganization, RhoA activation, and acquisition of a motile phenotype [72] . In this model, EGF stimulates src-mediated caveolin-1 phosphorylation, perhaps as a consequence of src activation by TGF-β1 (53) , and RhoA/ROCK signaling that, in turn, promotes EGF-as well as TGF-β1-induced VSMC migration, as seen in Figure 3 . However, other mechanisms of pathway mobilization are also evident. The apoptosis-inducing ligand TRAIL promotes the localization and activation of src kinase into lipid raft structures, facilitating complex formation with both the EGFR and caveolin-1 [73] . A src inhibitor blocked such interactions while caveolin-1 knockdown attenuated EGFR phosphorylation. Moreover, desmoglein 2 recruits caveolin-1, EGFR and src to membrane rafts and modulates EGFR signaling; overexpression of desmoglein 2 enhances EGFR activation and increases src-/EGFR-dependent cell proliferation and migration [74] . Similarly, TGF-β1 induces PAI-1 expression and the TGF-β1-or EGF-mediated acquisition of a motile phenotype in VSMCs involves pp60 c-src , EGFR Y845 , and RhoA/ROCK signaling; at the same time, caveolin-1 is required for TGF-β1-initiated EGFR transactivation [51, 53, 75] . Even publications that report divergent findings related to the involvement of caveolin-1 in EGF-dependent EGFR activation and cell migration, a key aspect of VSMC dysfunction in cardiovascular disease, conclude that caveolin-1 overexpression inhibits growth of various cells including VSMCs [76] [77] [78] , a prelude to entry into a senescent end-state.
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